Fig 1: Comparison of the expression of (A) CCL18, (B) CXCL1, (C) C1D, (D) TM4SF1, (E) FXR1, and (F) ZNF573 in ovarian cancer and normal tissues in TCGA and GTEx databases
Fig 2: (A) Detection flow chart of the Flow Fluorescence Technology. (B) A dose-response standard curve of serum CCL18 and CXCL1 antigens detection. (C) A dose-response standard curve of C1D, TM4SF1, FXR1, and ZNF573 IgG autoantibodies detection
Fig 3: Comparison of serum levels of CCL18 and CXCL1 antigens and C1D, FXR1, ZNF573, and TM4SF1 IgG autoantibodies in ovarian cancer group and other groups
Fig 4: Survival curves of serum (A) CCL18 antigen, (B) CXCL1 antigen, (C) C1D IgG autoantibodies, (D) FXR1 IgG autoantibodies, (E) TM4SF1 IgG autoantibodies, and (F) ZNF573 IgG autoantibodies in patients with ovarian cancer
Fig 5: Violin image of immune cell infiltration. (A) Violin image of immune cell infiltration in the CCL18 group. (B) Violin image of immune cell infiltration in the TM4SF1 group
Supplier Page from Abcam for Anti-CCL18 antibody - BSA and Azide free (Capture)